New combo therapy aims to shrink untreatable liver tumors
NCT ID NCT07334483
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of radioactive beads (yttrium-90), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib) works better than standard chemoembolization for liver cancer that cannot be surgically removed. About 120 adults with non-metastatic liver cancer will be randomly assigned to different treatment groups. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yttrium-90 microspheres (radioactive beads), camrelizumab (immunotherapy), apatinib (targeted therapy)
What this could lead to
If successful, this could offer a more effective treatment option for people with liver cancer that cannot be removed by surgery, potentially shrinking tumors better than current standard therapy.
What could go wrong
This is a mid-stage trial with only 120 participants, so results may not apply to everyone. Combining treatments also raises the risk of side effects like liver damage or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nanjing Tianyinshan Hospital
NOT_YET_RECRUITINGNanjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••